AURKA and neoplasm: The fact that alisertib, as a single agent or as part of a combination therapy regimen showed clinical activity in a subset of patients, underscores the need to improve our understanding of AURKA-regulated pathways that mediate tumor progression, including novel non-mitotic functions [17, 21–26].